Mucormycosis
📧 Sign up to get email alerts when something new happens for Mucormycosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-12EMA Authorised: Posaconazole Accord (posaconazole) — Accord Healthcare S.L.U.
Authorised status for Posaconazole Accord, MAH Accord Healthcare S.L.U., in the therapeutic area of mycoses.
-
FDA approval · 2025-06-02FDA Approved: AMPHOTERICIN B — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved an original application for Amphotericin B as a generic drug by Heritage Pharmaceuticals (Avet) to treat serious systemic funga…
-
FDA approval · 2025-03-24FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for CRESEMBA (isavuconazonium sulfate) filed by Astellas Pharma US, Inc.
-
FDA approval · 2025-03-13FDA Approved: POSACONAZOLE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for posaconazole from Mylan Institutional LLC, updating the approval for the generic product.
-
EMA approval · 2025-01-21EMA Authorised: Posaconazole AHCL (posaconazole) — Accord Healthcare S.L.U.
EMA authorised Posaconazole AHCL by Accord Healthcare S.L.U. for mycoses. The EU marketing authorization was granted on 16 January 2025.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-12-23FDA Approved: POSACONAZOLE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' posaconazole under an Original Application (ANDA), marking a generic approval for this antifungal.
-
FDA approval · 2023-08-28FDA Approved: POSACONAZOLE — Original Application (i3 Pharmaceuticals, LLC)
FDA approved an original application for posaconazole from i3 Pharmaceuticals, LLC (generic posaconazole).
-
FDA approval · 2022-11-17FDA Approved: AMPHOTERICIN B — Original Application (Eugia US LLC)
FDA approved the original ANDA for Amphotericin B from Eugia US LLC, authorizing a generic Amphotericin B product.
-
FDA approval · 2022-07-28FDA Approved: POSACONAZOLE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for posaconazole delayed-release (POSACONAZOLE DELAYED-RELEASE) from Chartwell RX, LLC, updating its…
-
FDA approval · 2022-05-25FDA Approved: POSACONAZOLE — Original Application (Par Health USA, LLC)
FDA approved the original application for posaconazole (generic) by Par Health USA, LLC, marking the availability of a generic posaconazole …
-
FDA approval · 2022-02-17FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for CRESEMBA (isavuconazonium sulfate) submitted by Astellas Pharma US, expanding the approval throu…
-
FDA approval · 2022-02-17FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for Cresemba (isavuconazonium sulfate) filed by Astellas Pharma US, expanding its approved use.
-
FDA approval · 2022-02-04FDA Approved: POSACONAZOLE — Original Application (Biocon Phama Inc.)
FDA approved Biocon Phama Inc.'s original application for posaconazole, authorizing a generic formulation of the antifungal agent.
-
FDA approval · 2021-12-14FDA Approved: AMPHOTERICIN B — Original Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical Industries' original application for Amphotericin B, confirming a generic version of the antifungal. The…
-
FDA approval · 2021-12-09FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for Cresemba (isavuconazonium sulfate) submitted by Astellas Pharma US, Inc.
-
FDA approval · 2021-05-18FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for Cresemba (isavuconazonium sulfate) filed by Astellas Pharma US, Inc. The approval adds to the ex…
-
FDA approval · 2021-04-22FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved Astellas' supplemental application for Cresemba (isavuconazonium sulfate), finalizing changes to its labeling. The action u…
-
FDA approval · 2020-09-16FDA Approved: NOXAFIL — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved Merck's supplemental application for NOXAFIL (posaconazole), updating the product labeling with new indications/usage detai…
-
FDA approval · 2016-01-05FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for Cresemba (isavuconazonium sulfate) from Astellas Pharma US, expanding its approved indications. …
-
FDA approval · 2015-04-03FDA Approved: CRESEMBA — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for CRESEMBA (isavuconazonium sulfate) from Astellas Pharma US, Inc., to support changes to the prod…
-
FDA approval · 2015-03-06FDA Approved: CRESEMBA — Original Application (Astellas Pharma US, Inc.)
FDA approves Cresemba (isavuconazonium sulfate) under an original application for the treatment of invasive aspergillosis and mucormycosis.
-
FDA approval · 2013-11-25FDA Approved: NOXAFIL — Original Application (Merck Sharp & Dohme LLC)
FDA approves NOXAFIL (posaconazole) through Merck's original NDA. The approval recognizes posaconazole for prevention and treatment of invas…
-
FDA approval · 2010-03-05FDA Approved: AMPHOTERICIN B — Supplemental Application (XGen Pharmaceuticals DJB, Inc.)
FDA approved a supplemental application for Amphotericin B submitted by XGen Pharmaceuticals DJB, Inc. This approval authorizes a change to …
-
FDA approval · 2006-09-15FDA Approved: NOXAFIL — Original Application (Merck Sharp & Dohme LLC)
NOXAFIL (posaconazole) received FDA approval through its original application as a broad-spectrum antifungal agent for the prevention of inv…